PFE logo
Pfizer Inc.
PFE
26.92 (-1.10%) 0.30
Health Care
Pharmaceuticals
Pfizer Inc. discovers develops manufactures markets distributes and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma PC1 and Pfizer Ignite. The company offers internal medicine products including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family Abrysvo Nimenrix FSME/IMMUN-TicoVac and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products such as Xeljanz Enbrel Cibinqo Litfulo Eucrisa and Velsipity; rare disease products for therapeutic areas comprising amyloidosis hemophilia and endocrine diseases under the Vyndaqel family Genotropin BeneFIX Xyntha Somavert Ngenla and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta Octagam and Panzyga brands. In addition the company offers oncology products comprising ADCs small molecules bispecific and other immunotherapies for the treatment of cancers including breast cancer genitourinary cancer and hematologic malignancies as well as melanoma gastrointestinal gynecological and lung cancer under the Ibrance Xtandi Padcev Adcetris Inlyta Lorbrena Bosulif Tukysa Braftovi Mektovi Orgovyx Elrexfio Tivdak and Talzenna brands. Further it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit Ruxience Zirabev Trazimera and Nivestym and other biosimilars; and sterile injectables such as Sulperazon Atgam Fragmin Solu Medrol Solu Cortef and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US Inc.; Merck KGaA; and BioNTech SE as well as a strategic collaboration with Boltz PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York New York.

Quality Checklist 3/8

Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
5Y Shares Out Change < 0%
ROIC > 10%
Quick Ratio > 1
Past Net Income CAGR > 0%
Est. EPS Growth > 5%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $153.13(B)
EV: $214.59(B)
Total Equity: $86.78(B)
Earnings date: May-05-2026
P/E: 19.65
Forward P/E: 9.09
P/FCF: 16.82
P/S: 2.45
P/B: 1.77
EPS: $1.4
EPS (fwd): $3.0
FCF/share: $1.6
Revenue/share: $11.0
Book value/share: $15.2
ROIC: 6.3%
ROA: 4.6%
ROE: 10.6%
Debt/Equity: 0.78
Current Ratio: 1.20
Gross margin: 75.8%
Operating margin: 24.6%
Net margin: 12.4%
Dividend/share: $1.7
Div. yield: 6.39%

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.10%
Institutions: 67.77%
Other: 32.13%

Institutional ownership

9.52% Vanguard Group Inc8.67% Blackrock Inc.5.28% State Street Corporati...2.29% Geode Capital Manageme...1.57% Morgan Stanley1.29% NORGES BANK1.11% Northern Trust Corpora...0.98% Massachusetts Financia...0.96% State Farm Mutual Auto...0.92% Wellington Management ...35.18% Others

Trading Summary

In the past year, insiders have bought $0.00 worth of the company's stock, and sold $0.00.

Congress members have bought between $42014 - $280000 worth of the company's stock, and sold between $187018 - $680000.

Insider transactions

$0.002026-05$0.00
$0.002026-04$0.00
$0.002026-03$0.00
$0.002026-02$0.00
$0.002026-01$0.00
$0.002025-12$0.00
$0.002025-11$0.00
$0.002025-10$0.00
$0.002025-09$0.00
$0.002025-08$0.00
$0.002025-07$0.00
$0.002025-06$0.00
$0.002025-05$0.00
DateSharesTotal ($)Price ($)NameTitle
Grant2026-03-0321,71900.0DAMICO JENNIFER B.Officer
Grant2026-02-2513,38300.0BOSHOFF CHRISTOFFELOfficer
Grant2026-02-25491,62616,626,79133.8BOURLA ALBERTChief Executive Officer
Grant2026-02-2517,558593,81233.8DAMICO JENNIFER B.Officer
Grant2026-02-2556,8881,923,95233.8SAHNI PAYALOfficer
Grant2026-02-2537,9251,282,62433.8MCDERMOTT MICHAELOfficer
Grant2026-02-25122,9074,156,71533.8LANKLER DOUGLAS MOfficer
Grant2026-02-2556,8881,923,95233.8FONSECA LIDIA PH.D.Officer

Congressional trading

$0.002026-05$0.00
$0.002026-04$0.00
$0.002026-03$0.00
$0.002026-02$0.00
$160012026-01$0.00
$1830012025-12$0.00
$0.002025-11$8001
$0.002025-10$0.00
$320022025-09$0.00
$160012025-08$24002
$0.002025-07$16001
$160012025-06$24002
$0.002025-05$81002
DatePoliticianPartyChamberAmount ($)
Sell2026-01-22Ro KhannaDHouse$1,001 - $15,000
Sell2026-01-22Ro KhannaDHouse$1,001 - $15,000
Sell2025-12-31J. French HillRHouse$100,001 - $250,000
Sell2025-12-19Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Buy2025-11-18Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Sell2025-09-15Ro KhannaDHouse$1,001 - $15,000
Sell2025-09-15Ro KhannaDHouse$1,001 - $15,000
Sell2025-09-15Ro KhannaDHouse$1,001 - $15,000
Sell2025-09-05Ro KhannaDHouse$1,001 - $15,000
Sell2025-08-05Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Buy2025-08-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-08-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-08-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-08-04Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-07-16Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-07-01Ro KhannaDHouse$1,001 - $15,000
Buy2025-06-20Ro KhannaDHouse$1,001 - $15,000
Buy2025-06-20Ro KhannaDHouse$1,001 - $15,000
Buy2025-06-17Julia LetlowRHouse$1,001 - $15,000
Sell2025-06-03Josh GottheimerDHouse$1,001 - $15,000
Sell2025-06-03Ron WydenDSenate$1,001 - $15,000
Buy2025-05-30Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Buy2025-05-28Ro KhannaDHouse$1,001 - $15,000
Buy2025-05-19Ro KhannaDHouse$15,001 - $50,000
Buy2025-05-15Rob BresnahanRHouse$15,001 - $50,000
Buy2025-04-29Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Sell2025-04-21Bruce WestermanRHouse$1,001 - $15,000
Sell2025-04-15Ro KhannaDHouse$15,001 - $50,000
Sell2025-04-11Jefferson ShreveRHouse$15,001 - $50,000
Sell2025-04-09Ro KhannaDHouse$15,001 - $50,000
Sell2025-04-08Rob BresnahanRHouse$15,001 - $50,000
Sell2025-03-31Gilbert Ray Cisneros, Jr.DHouse$15,001 - $50,000